Adjuvant Chemoendocrine Therapy May Be Associated With Cognitive Impairment

Results from a subgroup of the TAILORx trial suggested that adjuvant chemoendocrine therapy is associated with significantly greater cancer-related cognitive impairment compared with endocrine therapy alone.

Source: CancerNetwork - April 19, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news